LEONETTI, ALESSANDRO
LEONETTI, ALESSANDRO
Dipartimento di Medicina e Chirurgia
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC
2022-01-01 Mazzaschi, G.; Moron Dalla Tor, L.; Balbi, M.; Milanese, G.; Tognazzi, D.; Lorusso, B.; Trentini, F.; Di Rienzo, G.; Verzè, M.; Pluchino, M.; Minari, R.; Leo, L.; Gnetti, L.; Bordi, P.; Leonetti, A.; Ampollini, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy
2021-01-01 Mazzaschi, G.; Scandino, R.; Milanese, G.; Pavone, C.; Maurizio, B.; Silva, M.; Ledda, R.; Minari, R.; Trentini, F.; Buti, S.; Bordi, P.; Leonetti, A.; Quaini, F.; Sverzellati, N.; Romanel, A.; Tiseo, M.
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients
2021-01-01 Mazzaschi, G.; Milanese, G.; Moron Dalla Tor, L.; Leo, L.; Balbi, M.; Trentini, F.; Manini, M.; Pavone, C.; Silva, M.; Ledda, R. E.; Minari, R.; Bordi, P.; Buti, S.; Leonetti, A.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC
2023-01-01 Mazzaschi, G.; Bocchialini, G.; Lorusso, B.; Pluchino, M.; Trentini, F.; Di Rienzo, G.; Cattadori, S.; Tor, L. Moron Dalla; Verzè, M.; Minari, R.; Bordi, P.; Leonetti, A.; D’Agnelli, S.; Milanese, G.; Leo, L.; Gnetti, L.; Roti, G.; Ampollini, L.; Quaini, F.; Sverzellati, N.; Tiseo, M.
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients
2020-01-01 Mazzaschi, G.; Minari, R.; Ferri, V.; Bordi, P.; Gnetti, L.; Bersanelli, M.; Cavazzoni, A.; Buti, S.; Leonetti, A.; Zecca, A.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mori, C.; Petronini, P. G.; Missale, G.; Quaini, F.; Tiseo, M.
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients
2023-01-01 Mazzaschi, G.; Cardinale, E.; Pluchino, M.; Monica, G.; Lorusso, B.; D'Agnelli, S.; Trentini, F.; Tamarozzi, P.; Dalla Tor, L. Moron; Verzè, M.; Minari, R.; Bordi, P.; Perrone, F.; Leonetti, A.; Gnetti, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors
2022-01-01 Mazzaschi, G.; Tamarozzi, P.; Lorusso, B.; Verzè, M.; Pluchino, M.; Trentini, F.; Dalla Valle, B.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Moron Dalla Tor, L.; Leo, L.; Milanese, G.; Balbi, M.; Buti, S.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M.
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients
2021-01-01 Mazzaschi, G.; Minari, R.; Gnetti, L.; Campanini, N.; Zielli, T.; Baucina, M.; Perrone, F.; Leonetti, A.; Quaini, F.; Tiseo, M.
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?
2021-01-01 Leonetti, A.; Carbone, D.; Gregori, A.; Tiseo, M.; Peters, G. J.; Deng, D.; Giovannetti, E.
Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present)
2018-01-01 Leonetti, A.; Zielli, T.; Buti, S.
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib
2021-01-01 Minari, R.; Leonetti, A.; Gnetti, L.; Zielli, T.; Ventura, L.; Bottarelli, L.; Lagrasta, C.; la Monica, S.; Petronini, P. G.; Alfieri, R.; Tiseo, M.
Can we optimize the selection of patients with lung cancer suitable for EGFR+MET double inhibition?
2019-01-01 Leonetti, A.; Tiseo, M.; Rolfo, C.; Van Der Steen, N.; Peters, G. J.; Giovannetti, E.
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
2020-01-01 Bersanelli, M.; Buti, S.; Giannarelli, D.; Leonetti, A.; Cortellini, A.; Russo, G. L.; Signorelli, D.; Toschi, L.; Milella, M.; Pilotto, S.; Bria, E.; Proto, C.; Marinello, A.; Randon, G.; Rossi, S.; Vita, E.; Sartori, G.; D'Argento, E.; Qako, E.; Giaiacopi, E.; Ghilardi, L.; Bettini, A. C.; Rapacchi, E.; Mazzoni, F.; Lavacchi, D.; Scotti, V.; Ciccone, L. P.; De Tursi, M.; Di Marino, P.; Santini, D.; Russano, M.; Bordi, P.; Di Maio, M.; Audisio, M.; Filetti, M.; Giusti, R.; Berardi, R.; Fiordoliva, I.; Cerea, G.; Pizzutilo, E. G.; Bearz, A.; De Carlo, E.; Cecere, F.; Renna, D.; Camisa, R.; Caruso, G.; Ficorella, C.; Banna, G. L.; Cortinovis, D.; Brighenti, M.; Garassino, M. C.; Tiseo, M.
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy
2020-01-01 Bersanelli, M.; Zielli, T.; Perrone, F.; Casartelli, C.; Prattico, F.; Rapacchi, E.; Camisa, R.; Tognetto, M.; Clemente, A.; Giannarelli, D.; Rebuzzi, S. E.; Leonetti, A.; Bordi, P.; Tiseo, M.; Buti, S.
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study
2021-01-01 Buti, S.; Perrone, F.; Zielli, T.; Mazzaschi, G.; Casartelli, C.; Leonetti, A.; Milanese, G.; Silva, M.; Eufrasia Ledda, R.; Musolino, A.; Pucci, F.; Bersanelli, M.; Tiseo, M.
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY
2023-01-01 Leonetti, Alessandro; Peroni, Marianna; Agnetti, Virginia; Pratticò, Fabiana; Manini, Martina; Acunzo, Alessandro; Marverti, Francesca; Sulas, Simone; Rapacchi, Elena; Mazzaschi, Giulia; Perrone, Fabiana; Bordi, Paola; Buti, Sebastiano; Tiseo, Marcello
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
2017-01-01 Leonetti, A.; Leonardi, F.; Bersanelli, M.; Buti, S.
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors
2020-01-01 Leonetti, A.; Facchinetti, F.; Zielli, T.; Brianti, E.; Tiseo, M.
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis
2021-01-01 Leonetti, A.; Capula, M.; Minari, R.; Mazzaschi, G.; Gregori, A.; El Hassouni, B.; Papini, F.; Bordi, P.; Verze, M.; Avan, A.; Tiseo, M.; Giovannetti, E.
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens
2022-01-01 Mazzaschi, G; Verze, M; Tognazzi, D; Lorusso, B; Minari, R; Pluchino, M; Trentini, F; Manini, M; Bordi, P; Leonetti, A; Perrone, F; Coriano, M; Casali, M; Toscani, I; Cosenza, A; Ferri, L; Buti, S; Sverzellati, N; Quaini, F; Tiseo, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC | 1-gen-2022 | Mazzaschi, G.; Moron Dalla Tor, L.; Balbi, M.; Milanese, G.; Tognazzi, D.; Lorusso, B.; Trentini, F.; Di Rienzo, G.; Verzè, M.; Pluchino, M.; Minari, R.; Leo, L.; Gnetti, L.; Bordi, P.; Leonetti, A.; Ampollini, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy | 1-gen-2021 | Mazzaschi, G.; Scandino, R.; Milanese, G.; Pavone, C.; Maurizio, B.; Silva, M.; Ledda, R.; Minari, R.; Trentini, F.; Buti, S.; Bordi, P.; Leonetti, A.; Quaini, F.; Sverzellati, N.; Romanel, A.; Tiseo, M. | |
| 17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients | 1-gen-2021 | Mazzaschi, G.; Milanese, G.; Moron Dalla Tor, L.; Leo, L.; Balbi, M.; Trentini, F.; Manini, M.; Pavone, C.; Silva, M.; Ledda, R. E.; Minari, R.; Bordi, P.; Buti, S.; Leonetti, A.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC | 1-gen-2023 | Mazzaschi, G.; Bocchialini, G.; Lorusso, B.; Pluchino, M.; Trentini, F.; Di Rienzo, G.; Cattadori, S.; Tor, L. Moron Dalla; Verzè, M.; Minari, R.; Bordi, P.; Leonetti, A.; D’Agnelli, S.; Milanese, G.; Leo, L.; Gnetti, L.; Roti, G.; Ampollini, L.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients | 1-gen-2020 | Mazzaschi, G.; Minari, R.; Ferri, V.; Bordi, P.; Gnetti, L.; Bersanelli, M.; Cavazzoni, A.; Buti, S.; Leonetti, A.; Zecca, A.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mori, C.; Petronini, P. G.; Missale, G.; Quaini, F.; Tiseo, M. | |
| 2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients | 1-gen-2023 | Mazzaschi, G.; Cardinale, E.; Pluchino, M.; Monica, G.; Lorusso, B.; D'Agnelli, S.; Trentini, F.; Tamarozzi, P.; Dalla Tor, L. Moron; Verzè, M.; Minari, R.; Bordi, P.; Perrone, F.; Leonetti, A.; Gnetti, L.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors | 1-gen-2022 | Mazzaschi, G.; Tamarozzi, P.; Lorusso, B.; Verzè, M.; Pluchino, M.; Trentini, F.; Dalla Valle, B.; Minari, R.; Perrone, F.; Bordi, P.; Leonetti, A.; Moron Dalla Tor, L.; Leo, L.; Milanese, G.; Balbi, M.; Buti, S.; Roti, G.; Quaini, F.; Sverzellati, N.; Tiseo, M. | |
| 7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients | 1-gen-2021 | Mazzaschi, G.; Minari, R.; Gnetti, L.; Campanini, N.; Zielli, T.; Baucina, M.; Perrone, F.; Leonetti, A.; Quaini, F.; Tiseo, M. | |
| A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? | 1-gen-2021 | Leonetti, A.; Carbone, D.; Gregori, A.; Tiseo, M.; Peters, G. J.; Deng, D.; Giovannetti, E. | |
| Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) | 1-gen-2018 | Leonetti, A.; Zielli, T.; Buti, S. | |
| Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib | 1-gen-2021 | Minari, R.; Leonetti, A.; Gnetti, L.; Zielli, T.; Ventura, L.; Bottarelli, L.; Lagrasta, C.; la Monica, S.; Petronini, P. G.; Alfieri, R.; Tiseo, M. | |
| Can we optimize the selection of patients with lung cancer suitable for EGFR+MET double inhibition? | 1-gen-2019 | Leonetti, A.; Tiseo, M.; Rolfo, C.; Van Der Steen, N.; Peters, G. J.; Giovannetti, E. | |
| Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study | 1-gen-2020 | Bersanelli, M.; Buti, S.; Giannarelli, D.; Leonetti, A.; Cortellini, A.; Russo, G. L.; Signorelli, D.; Toschi, L.; Milella, M.; Pilotto, S.; Bria, E.; Proto, C.; Marinello, A.; Randon, G.; Rossi, S.; Vita, E.; Sartori, G.; D'Argento, E.; Qako, E.; Giaiacopi, E.; Ghilardi, L.; Bettini, A. C.; Rapacchi, E.; Mazzoni, F.; Lavacchi, D.; Scotti, V.; Ciccone, L. P.; De Tursi, M.; Di Marino, P.; Santini, D.; Russano, M.; Bordi, P.; Di Maio, M.; Audisio, M.; Filetti, M.; Giusti, R.; Berardi, R.; Fiordoliva, I.; Cerea, G.; Pizzutilo, E. G.; Bearz, A.; De Carlo, E.; Cecere, F.; Renna, D.; Camisa, R.; Caruso, G.; Ficorella, C.; Banna, G. L.; Cortinovis, D.; Brighenti, M.; Garassino, M. C.; Tiseo, M. | |
| Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy | 1-gen-2020 | Bersanelli, M.; Zielli, T.; Perrone, F.; Casartelli, C.; Prattico, F.; Rapacchi, E.; Camisa, R.; Tognetto, M.; Clemente, A.; Giannarelli, D.; Rebuzzi, S. E.; Leonetti, A.; Bordi, P.; Tiseo, M.; Buti, S. | |
| Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study | 1-gen-2021 | Buti, S.; Perrone, F.; Zielli, T.; Mazzaschi, G.; Casartelli, C.; Leonetti, A.; Milanese, G.; Silva, M.; Eufrasia Ledda, R.; Musolino, A.; Pucci, F.; Bersanelli, M.; Tiseo, M. | |
| CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY | 1-gen-2023 | Leonetti, Alessandro; Peroni, Marianna; Agnetti, Virginia; Pratticò, Fabiana; Manini, Martina; Acunzo, Alessandro; Marverti, Francesca; Sulas, Simone; Rapacchi, Elena; Mazzaschi, Giulia; Perrone, Fabiana; Bordi, Paola; Buti, Sebastiano; Tiseo, Marcello | |
| Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma | 1-gen-2017 | Leonetti, A.; Leonardi, F.; Bersanelli, M.; Buti, S. | |
| COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors | 1-gen-2020 | Leonetti, A.; Facchinetti, F.; Zielli, T.; Brianti, E.; Tiseo, M. | |
| Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis | 1-gen-2021 | Leonetti, A.; Capula, M.; Minari, R.; Mazzaschi, G.; Gregori, A.; El Hassouni, B.; Papini, F.; Bordi, P.; Verze, M.; Avan, A.; Tiseo, M.; Giovannetti, E. | |
| Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens | 1-gen-2022 | Mazzaschi, G; Verze, M; Tognazzi, D; Lorusso, B; Minari, R; Pluchino, M; Trentini, F; Manini, M; Bordi, P; Leonetti, A; Perrone, F; Coriano, M; Casali, M; Toscani, I; Cosenza, A; Ferri, L; Buti, S; Sverzellati, N; Quaini, F; Tiseo, M |